Hypoxia increases Annexin A2 expression in osteoblastic cells via VEGF and ERK

Damian C Genetos, Alice Wong, Shinya Watari, Clare E Yellowley-genetos

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF)-stimulated angiogenesis is critical for endochondral ossification that occurs during bone development and bone repair. Under these circumstances, VEGF production appears to be driven by low oxygen tension, under the control of the hypoxia-inducible factor-α family of transcription factors (HIF-α). Annexin 2 (AnxA2) a calcium-dependent phospholipid binding protein has been implicated in VEGF-mediated retinal neovascularization and is upregulated by VEGF in choroid retinal endothelial cells. AnxA2 is also expressed in cells of the osteoblast lineage and chondrocytes and may play a role in matrix mineralization. In this paper, we examined the effects of hypoxia (1% O2) and VEGF on the expression of AnxA2 in osteoblastic MC3T3-E1 cells. Hypoxia, desferrioxamine (hypoxia mimetic), and recombinant VEGF all increased AnxA2 mRNA and protein levels in osteoblastic cells. The hypoxia-induced increase in AnxA2 was inhibited by a blocking antibody to VEGF-R1; however, VEGF120, a VEGF-R1 agonist, demonstrated no influence upon Anxa2 expression. This suggests that VEGF induction of Annexin A2 is not mediated via VEGF-R1 agonism alone but by VEGF-R1 and Neuropilin-1 or Neuropilin-2 heterodimers. In addition, we demonstrated that VEGF-stimulated changes in AnxA2 expression via a pathway involving Src and MEK kinase. These data demonstrate that AnxA2 expression in osteoblasts is under the control of VEGF, which may have implications for both angiogenesis and bone mineralization under low oxygen conditions.

Original languageEnglish (US)
Pages (from-to)1013-1019
Number of pages7
JournalBone
Volume47
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

Annexin A2
Vascular Endothelial Growth Factor A
Osteoblasts
Hypoxia
Neuropilin-2
Neuropilin-1
Retinal Neovascularization
Oxygen
MAP Kinase Kinase Kinases
Annexins
Physiologic Calcification
Blocking Antibodies
Deferoxamine
Choroid
src-Family Kinases
Bone Development
Cell Lineage
Chondrocytes
Osteogenesis

Keywords

  • Annexin A2
  • ERK
  • Hypoxia
  • Osteoblast
  • Src
  • VEGF

ASJC Scopus subject areas

  • Physiology
  • Endocrinology, Diabetes and Metabolism
  • Histology

Cite this

Hypoxia increases Annexin A2 expression in osteoblastic cells via VEGF and ERK. / Genetos, Damian C; Wong, Alice; Watari, Shinya; Yellowley-genetos, Clare E.

In: Bone, Vol. 47, No. 6, 12.2010, p. 1013-1019.

Research output: Contribution to journalArticle

@article{fa5e49fc92d44efd88f0bd7ecf2666e0,
title = "Hypoxia increases Annexin A2 expression in osteoblastic cells via VEGF and ERK",
abstract = "Vascular endothelial growth factor (VEGF)-stimulated angiogenesis is critical for endochondral ossification that occurs during bone development and bone repair. Under these circumstances, VEGF production appears to be driven by low oxygen tension, under the control of the hypoxia-inducible factor-α family of transcription factors (HIF-α). Annexin 2 (AnxA2) a calcium-dependent phospholipid binding protein has been implicated in VEGF-mediated retinal neovascularization and is upregulated by VEGF in choroid retinal endothelial cells. AnxA2 is also expressed in cells of the osteoblast lineage and chondrocytes and may play a role in matrix mineralization. In this paper, we examined the effects of hypoxia (1{\%} O2) and VEGF on the expression of AnxA2 in osteoblastic MC3T3-E1 cells. Hypoxia, desferrioxamine (hypoxia mimetic), and recombinant VEGF all increased AnxA2 mRNA and protein levels in osteoblastic cells. The hypoxia-induced increase in AnxA2 was inhibited by a blocking antibody to VEGF-R1; however, VEGF120, a VEGF-R1 agonist, demonstrated no influence upon Anxa2 expression. This suggests that VEGF induction of Annexin A2 is not mediated via VEGF-R1 agonism alone but by VEGF-R1 and Neuropilin-1 or Neuropilin-2 heterodimers. In addition, we demonstrated that VEGF-stimulated changes in AnxA2 expression via a pathway involving Src and MEK kinase. These data demonstrate that AnxA2 expression in osteoblasts is under the control of VEGF, which may have implications for both angiogenesis and bone mineralization under low oxygen conditions.",
keywords = "Annexin A2, ERK, Hypoxia, Osteoblast, Src, VEGF",
author = "Genetos, {Damian C} and Alice Wong and Shinya Watari and Yellowley-genetos, {Clare E}",
year = "2010",
month = "12",
doi = "10.1016/j.bone.2010.08.024",
language = "English (US)",
volume = "47",
pages = "1013--1019",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Hypoxia increases Annexin A2 expression in osteoblastic cells via VEGF and ERK

AU - Genetos, Damian C

AU - Wong, Alice

AU - Watari, Shinya

AU - Yellowley-genetos, Clare E

PY - 2010/12

Y1 - 2010/12

N2 - Vascular endothelial growth factor (VEGF)-stimulated angiogenesis is critical for endochondral ossification that occurs during bone development and bone repair. Under these circumstances, VEGF production appears to be driven by low oxygen tension, under the control of the hypoxia-inducible factor-α family of transcription factors (HIF-α). Annexin 2 (AnxA2) a calcium-dependent phospholipid binding protein has been implicated in VEGF-mediated retinal neovascularization and is upregulated by VEGF in choroid retinal endothelial cells. AnxA2 is also expressed in cells of the osteoblast lineage and chondrocytes and may play a role in matrix mineralization. In this paper, we examined the effects of hypoxia (1% O2) and VEGF on the expression of AnxA2 in osteoblastic MC3T3-E1 cells. Hypoxia, desferrioxamine (hypoxia mimetic), and recombinant VEGF all increased AnxA2 mRNA and protein levels in osteoblastic cells. The hypoxia-induced increase in AnxA2 was inhibited by a blocking antibody to VEGF-R1; however, VEGF120, a VEGF-R1 agonist, demonstrated no influence upon Anxa2 expression. This suggests that VEGF induction of Annexin A2 is not mediated via VEGF-R1 agonism alone but by VEGF-R1 and Neuropilin-1 or Neuropilin-2 heterodimers. In addition, we demonstrated that VEGF-stimulated changes in AnxA2 expression via a pathway involving Src and MEK kinase. These data demonstrate that AnxA2 expression in osteoblasts is under the control of VEGF, which may have implications for both angiogenesis and bone mineralization under low oxygen conditions.

AB - Vascular endothelial growth factor (VEGF)-stimulated angiogenesis is critical for endochondral ossification that occurs during bone development and bone repair. Under these circumstances, VEGF production appears to be driven by low oxygen tension, under the control of the hypoxia-inducible factor-α family of transcription factors (HIF-α). Annexin 2 (AnxA2) a calcium-dependent phospholipid binding protein has been implicated in VEGF-mediated retinal neovascularization and is upregulated by VEGF in choroid retinal endothelial cells. AnxA2 is also expressed in cells of the osteoblast lineage and chondrocytes and may play a role in matrix mineralization. In this paper, we examined the effects of hypoxia (1% O2) and VEGF on the expression of AnxA2 in osteoblastic MC3T3-E1 cells. Hypoxia, desferrioxamine (hypoxia mimetic), and recombinant VEGF all increased AnxA2 mRNA and protein levels in osteoblastic cells. The hypoxia-induced increase in AnxA2 was inhibited by a blocking antibody to VEGF-R1; however, VEGF120, a VEGF-R1 agonist, demonstrated no influence upon Anxa2 expression. This suggests that VEGF induction of Annexin A2 is not mediated via VEGF-R1 agonism alone but by VEGF-R1 and Neuropilin-1 or Neuropilin-2 heterodimers. In addition, we demonstrated that VEGF-stimulated changes in AnxA2 expression via a pathway involving Src and MEK kinase. These data demonstrate that AnxA2 expression in osteoblasts is under the control of VEGF, which may have implications for both angiogenesis and bone mineralization under low oxygen conditions.

KW - Annexin A2

KW - ERK

KW - Hypoxia

KW - Osteoblast

KW - Src

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=78049423866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049423866&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2010.08.024

DO - 10.1016/j.bone.2010.08.024

M3 - Article

C2 - 20817051

AN - SCOPUS:78049423866

VL - 47

SP - 1013

EP - 1019

JO - Bone

JF - Bone

SN - 8756-3282

IS - 6

ER -